Dr. Garassino on Immunotherapy in EGFR-Mutated Lung Cancer

Marina Chiara Garassino, MD
Published: Wednesday, Nov 01, 2017



Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses immunotherapy for patients with EGFR-mutated lung cancer.

Looking at the subgroup analysis for all randomized clinical trials, there is no clear benefit in EGFR-mutated patients, making it difficult to decide whether to treat with immunotherapy or chemotherapy, explains Garassino.

In the ATLANTIC trial, patients with EGFR-mutated lung cancer were treated with durvalumab (Imfinzi). These patients experienced a benefit with progression-free survival and overall survival, states Garassino.
 


Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses immunotherapy for patients with EGFR-mutated lung cancer.

Looking at the subgroup analysis for all randomized clinical trials, there is no clear benefit in EGFR-mutated patients, making it difficult to decide whether to treat with immunotherapy or chemotherapy, explains Garassino.

In the ATLANTIC trial, patients with EGFR-mutated lung cancer were treated with durvalumab (Imfinzi). These patients experienced a benefit with progression-free survival and overall survival, states Garassino.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Community Practice Connections™: 4th Annual Miami Lung Cancer Conference®Jun 30, 20187.0
Publication Bottom Border
Border Publication
x